Mylan (NASDAQ:MYL) was upgraded by equities researchers at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.
A number of other analysts have also issued reports on the stock. Zacks Investment Research raised shares of Mylan from a “sell” rating to a “hold” rating in a research note on Tuesday, January 16th. Wells Fargo set a $43.00 target price on shares of Mylan and gave the company a “hold” rating in a research note on Thursday, January 18th. TheStreet raised shares of Mylan from a “c” rating to a “b-” rating in a research note on Wednesday, January 17th. Morgan Stanley set a $50.00 target price on shares of Mylan and gave the company a “buy” rating in a research note on Monday, April 9th. Finally, JPMorgan Chase set a $53.00 price objective on Mylan and gave the company a “buy” rating in a report on Friday, February 16th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. Mylan currently has an average rating of “Buy” and an average target price of $47.02.
NASDAQ MYL opened at $40.08 on Wednesday. The company has a quick ratio of 0.65, a current ratio of 1.06 and a debt-to-equity ratio of 1.03. The firm has a market cap of $19.84 billion, a price-to-earnings ratio of 8.79, a PEG ratio of 1.25 and a beta of 1.35. Mylan has a 52 week low of $38.30 and a 52 week high of $39.07.
Mylan (NASDAQ:MYL) last issued its earnings results on Wednesday, May 9th. The company reported $0.96 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.99 by ($0.03). The company had revenue of $2.68 billion for the quarter, compared to analysts’ expectations of $2.74 billion. Mylan had a net margin of 6.04% and a return on equity of 18.56%. The firm’s revenue for the quarter was down 1.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.93 earnings per share. analysts predict that Mylan will post 5.36 EPS for the current fiscal year.
In other Mylan news, Director Robert J. Coury sold 150,000 shares of the business’s stock in a transaction dated Friday, March 2nd. The shares were sold at an average price of $40.10, for a total value of $6,015,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Paul Campbell sold 7,030 shares of the business’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $44.01, for a total transaction of $309,390.30. Following the completion of the transaction, the insider now owns 17,054 shares of the company’s stock, valued at $750,546.54. The disclosure for this sale can be found here. Insiders sold 269,287 shares of company stock valued at $11,034,960 over the last quarter. 0.69% of the stock is currently owned by corporate insiders.
Institutional investors have recently made changes to their positions in the business. Analyst IMS Investment Management Services Ltd. bought a new position in Mylan in the first quarter worth about $117,000. Rational Advisors LLC acquired a new position in shares of Mylan during the fourth quarter valued at about $190,000. Advisor Partners LLC acquired a new position in shares of Mylan during the fourth quarter valued at about $214,000. First Personal Financial Services increased its holdings in shares of Mylan by 77.1% during the fourth quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after acquiring an additional 2,106 shares in the last quarter. Finally, M Holdings Securities Inc. acquired a new position in shares of Mylan during the fourth quarter valued at about $383,000. Institutional investors and hedge funds own 83.53% of the company’s stock.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.